Today it was reported that the SVP, CFO and Secretary of MacroGenics (MGNX), James Karrels, exercised options to buy 3,000 MGNX shares at $0.94 a share, for a total transaction value of $2,820. The options were close to expired and James Karrels retained stocks.
This recent transaction increases James Karrels’ holding in the company by 2.61% to a total of $2.02 million. In addition to James Karrels, 2 other MGNX executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on MacroGenics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $20.8 million and GAAP net loss of $34.03 million. In comparison, last year the company earned revenue of $1.66 million and had a GAAP net loss of $47.04 million. Currently, MacroGenics has an average volume of 130.2K.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $31.33, reflecting a 91.9% upside. Starting in December 2017, MGNX received 28 Buy ratings in a row. Four different firms, including BTIG and Cowen & Co., currently also have a Buy rating on the stock.
The insider sentiment on MacroGenics has been positive according to 15 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
James Karrels’ trades have generated a 3.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its portfolio includes Margetuximab, Flotetuzumab, MGA012, MGD013, Enoblituzumab, MGD009, and Teplizumab.